

(P)

Cipla to name Gilead Sciences's hepatitis C generic drug Hepcvir

dna correspondent @dna

Mumbai: Pharmaceutical major Cipla plans to name its hepatitis C drug with Gilead Sciences as Hepcvir, its chairman Yusuf K Hamied on Wednesday. Last year Gilead Sciences has licensed its hepatitis C drug Sovaldi (chemically known as sofosbuvir) to seven India-based drugmakers including Cipla which will sell the cheap generic versions of the drug in 91 developing nations.

"Hepcvir is the brand name and we are working on it. We will apply probably for regulatory approval in the next couple of months and hopefully by middle of the year we will be in market for India. We have the stocks of the raw materials, we are already started making the raw materials, he said.

4
12/2
JSCSD - ontan

DIR(AK)

16/2

Consultant (CIVIL)

17-2-15

TD, NIC

Company